Measuring quality of life of primary antibody deficiency patients using a disease-specific health-related quality of life questionnaire for common variable immunodeficiency (CVID_QoL)

Journal of Patient-Reported Outcomes

Table 1 Demographic and clinical characteristics of the Norwegian and Italian [8] cohorts

	Norway N (%)	Italy [8] N (%)
Demographic characteristics
Total	83 (100)	118 (100)
Male	20 (24)	46 (39)
Female	63 (76)	72 (61)
Mean age (years, SD)	47 (16)	NA
Age ≤ 50 years	45 (54)	66 (56)
Age > 50 years	38 (46)	52 (44)
Education ≤13 years	37 (45)	31 (26)
Education > 13 years	45 (54)	87 (74)
No children < 18 years	61 (74)	NA
Children < 18 years	21 (25)	NA
Clinical characteristics
CVID	52 (63)	118 (100)
Other PAD	31 (37)	0 (0)
Mean disease duration (years, SD)	15 (12)*	12 (11)
SCIG	28 (88)**	13 (11)
IVIG	4 (13)**	105 (89)
BMI ≤ 18,5	3 (4)	9 (7)
BMI 18,6 - 24,9	39 (47)	67 (57)
BMI ≥ 25	27 (33)	42 (36)

NA = not available, CVID = common variable immunodeficiency, PAD = primary antibody deficiency, SCIG = subcutaneous immunoglobulin, IVIG = intravenous immunoglobulin, BMI = body mass index. N is reported as frequencies. Percentages (%) are calculated from the total number of patients in the respective samples unless specified otherwise. Some numbers were rounded so not all percentages total 100%.*Data only available for the patients recruited through the mail survey (n = 51).**Data only available for the patients recruited through the CRD seminar (n = 32)